'I am running a for-profit business': Mylan chief Heather Bresch defends EpiPen price hike

'I am running a for-profit business': Mylan chief Heather Bresch defends EpiPen price hike


As the chief executive of Mylan, the owner of the severe allergy treatment EpiPen, Bresch is at the centre of the latest public outrage over high drug prices, excoriated for overseeing a fourfold price increase on EpiPen while taking a huge pay raise. From talk shows to Twitter, her name is being mentioned alongside Martin Shkreli, the so-called Pharma Bro who ignited anger last fall over raising the price of the drug Daraprim , and J. Michael Pearson, the onetime McKinsey consultant who took over Valeant Pharmaceuticals International and sharply raised prices on lifesaving drugs.



from Biotech News